Authors
Latest:
Biomarkers for Response to Anti–PD-1/Anti–PD-L1 Immune Checkpoint Inhibitors: A Large Meta-AnalysisArshiya Mariam, BS, and colleagues report the findings of a large meta-analysis assessing the ability of various biomarkers to predict responses to immune checkpoint inhibition.
Latest:
Cancer Network Faceoff: Conclusion of the Event and Presentation of AwardFinal remarks and presentation of awards.
Latest:
Clinical Pearls about the Referral Process of Bispecifics and CAR-T in RRMMThe discussion shares key takeaways and practical insights for optimizing the referral and treatment process for CAR T-cell and bispecific therapies.
Latest:
Opsoclonus-Myoclonus–Associated Neuroblastoma With Bone Marrow Metastases: What Would Be the Best Treatment Option?In this clinical quandary, investigators determine how to best treat patients with opsoclonus-myoclonus–associated neuroblastoma with bone marrow metastases.
Latest:
Frontline Setting of Pancreatic CancerPanelists discuss how the frontline treatment of pancreatic cancer typically involves chemotherapy regimens such as FOLFIRINOX (leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin) or gemcitabine-based therapies, with decisions guided by tumor characteristics, patient performance status, and treatment goals, aiming to improve survival outcomes and quality of life in newly diagnosed patients.
Latest:
Treatment of Multiple Myeloma: Q&A Session With Yale Cancer Center and SatellitesA Q&A session with the expert panel.
Latest:
Exploring Next-Line Options: Therapies Beyond Trastuzumab Deruxtecan in HER2+ MSS Gastric CancerExperts discuss other therapies or clinical trials that might be explored after trastuzumab deruxtecan, particularly for patients with HER2-positive microsatellite-stable (MSS) adenocarcinoma and progression on multiple lines of therapy.
Latest:
Marshall Posner, MD, on the Promise of Personalized mRNA Vaccines in Solid MalignanciesMarshall Posner, MD, detailed the potential for personalized mRNA vaccines to treat patients with various different tumors and what information is still needed.
Latest:
Ongoing Trials May Elucidate Mosunetuzumab Efficacy in Follicular LymphomaInvestigators are currently evaluating mosunetuzumab in relapsed disease or comparing it with rituximab in treatment-naïve follicular lymphoma.
Latest:
“Promising” Data Support Blinatumomab in CD19+ B-ALL PopulationOverall survival data with blinatumomab in the phase 3 E1910 study may be an “important development” in CD19-positive B-ALL.
Latest:
Alison M. Schram, MD, Reviews Data of Zenocutuzumab in the Phase 2 eNRGy Trial for NRG1 Fusion–Positive CancersAlison M. Schram, MD, spoke about key findings from the phase 2 eNRGy trial assessing zenocutuzumab in patients with NRG1 fusion–positive advanced solid tumors.
Latest:
Hereditary Renal Tumor Syndromes and the Use of mTOR InhibitorsA 47-year-old woman with a history of drug-resistant epilepsy during childhood presented to the emergency department with sudden dyspnea and chest pain. Upon admission, her oxygen saturation was 88%.
Latest:
Integrative Oncology in Young Women With Breast CancerYancey Warren, Jr, MD, MAT, and colleagues investigate the use of integrative oncology services among young women with breast cancer.
Latest:
Clinical Scenario: AE Management for Bispecific Therapy in R/R MMFollowing the review of a case of a patient with relapsed/refractory multiple myeloma, the panel provides expert perspectives on adverse event management practices.
Latest:
Caring for Patients With Serious Mental Illness: Guide for the Oncology ClinicianVeronica B. Decker, DNP, MBA, APRN, PMHCNS-BC, and colleagues discuss how to care for patients with cancer and serious mental illness.
Latest:
Clinical Trials in Progress: COBRAPhase 2/3 Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA): a first-in-kind trial seeks to provide level 1 evidence in evaluating the role of ctDNA as a guide for clinicians in the decision to administer adjuvant chemotherapy to patients with stage IIA colon cancer (NRG GI-005) (NCT04068103).
